Font Size: A A A
State of Nevada releases statement on serious reactions to Janssen COVID-19 vaccine

State of Nevada releases statement on serious reactions to Janssen COVID-19 vaccine

Carson City, NV – During today’s public federal Advisory Committee on Immunization Practices (ACIP) meeting, the Nevada Department of Health and Human Services learned that a Nevadan was one of the six reported serious reactions to the Janssen COVID-19 vaccine.

The State of Nevada was not informed of this reported reaction until the live, public meeting on Wednesday.

On Tuesday, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) issued a joint statement recommending a pause in the use of the Janssen COVID-19 vaccine while six serious reactions were investigated.

Yesterday, the State of Nevada paused use of the vaccine and previously reported that none of the cases were located in Nevada. Following today’s ACIP announcement, DHHS immediately reached out to federal partners for more information and to understand why the report was not provided to the State.

As of Monday, more than 6.8 million doses of the Janssen vaccine have been administered in the United States.

People who have received the Janssen vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are required to report adverse events to the Vaccine Adverse Event Reporting System at


Immunize Nevada

Immunize Nevada, an award winning 501c3 non profit, is widely recognized as Nevada’s trusted resource for immunizations and community health for all ages by fostering education and statewide collaboration.